Health Advocacy, Inc.
Release Date:15 Jun 2017
Release Date:07 Jun 2017
Release Date:15 Jun 2017

Health Advocacy, Inc.

How Pharmaceutical Funding Changed the Breast Cancer Movement

UBC Press

Today, most patient groups in Canada are funded by the pharmaceutical industry, raising an important ethical question: do alliances between patient organizations and corporate sponsors ultimately lead to policies that are counter to the public interest? In this examination of Canada’s breast cancer movement from 1990 to 2010, health activist, scholar, and cancer survivor Sharon Batt investigates the relationship between patient advocacy groups and the pharmaceutical industry – and the hidden implications of pharma funding for health policy.

Health Advocacy, Inc. dissects the alliances between the companies that sell pharmaceuticals and the individuals who use them, drawing links between neoliberalism and corporate financing and the ensuing threat to the public health care system. Batt combines archival analysis, interviews with advocacy and industry representatives, and personal observation to reveal how a reduction in state funding drove patient groups to form partnerships with the private sector. The resulting power imbalance continues to challenge the groups’ ability to put patients’ interests ahead of those of the industry.

Batt’s conclusion is unsettling: a once-vibrant movement that encouraged democratic participation in the development of health policy now eerily echoes the demands of the pharmaceutical industry. This thorough account of the shift from grassroots advocacy to Big Pharma partnership defines the struggles and stakes of activism in public health today.

The book will be of value to scholars and students of medicine and health policy, public health, the sociology of health, women’s studies, science and technology studies, and political economy. It will also interest those involved in patient and health consumer advocacy groups, pharmaceutical policy, the breast cancer movement, and neoliberal governance.

Batt’s revelations about the relationship between patient advocacy groups and the pharmaceutical industry are vital and disturbing. Lisa Cumming, Maisonneuve
Sharon Batt catalogues with exquisite and agonizing precision the predatory funding by drug companies of breast-cancer–patient advocacy groups and the consequent loss of authenticity and trustworthiness of breast cancer advocates. It is an alarming historical record and inseparable from government cuts to patient groups and the infiltration of corporate values into patient care and activism. Philip B. Berger, MD, long-time downtown Toronto physic
Sharon Batt has given us a riveting account of how health advocacy in Canada became colonized by the pharmaceutical industry. As a leader in the breast cancer and women’s health movement, she provides a compassionate and scholarly overview of the moral and ethical dilemmas many health activists faced when Big Pharma came knocking at the door. Health Advocacy, Inc. describes the public policies that were behind these heart-wrenching debates on the front lines and provides a roadmap back to independence. Colleen Fuller, cofounder and president, PharmaWatch Canada
This is a powerful insider account, coupled with excellent scholarship, of Big Pharma’s doings in relation to the breast cancer movement. After reading this book, the only thing I wanted was more – more information on how this work applies to other countries and to other health advocacy movements. This is a vitally important book. Evelyne de Leeuw, director of the Centre for Health Equity Training Research and Evaluation (CHETRE) at the University of New South Wales, Australia
A searing indictment of industry subversion of “patient” groups. Batt chronicles the rise of industry fronts and industry-influenced patient groups that arose in parallel with (and as a result of) the rise of neoliberalism. She demonstrates how the same tools used by industry to influence doctors are used to influence key patient groups in ways that patients may not recognize. Required reading for all lay groups tempted by industry money. Jeanne Lenzer, associate editor of British Medical Journal, and author of The Danger within Us: America’s Untested, Unregulated Medical Device Industry and One Man’s Battle to Survive It
I recommend this book to anyone who wants to understand the government policy changes and the manipulations, conflicts of interest, and very human dynamics that undermined the integrity of the breast cancer patient/survivor movement and skewed patient advocacy towards pharmaceutical industry interests. Sharon Batt’s meticulous research lays bare the troubling dynamics of drug industry funding and explores better ways to protect women’s health. Ann Silversides, award-winning health policy journalist and author of AIDS Activist: Michael Lynch and the Politics of Community
Sharon Batt’s thorough and detailed book revisits some key history around breast cancer activism, pointing out, for example, the serious conflict of interest that shaped the work of the prominent women’s health movement advocate Rose Kushner. Batt both “follows the money” and also offers a sympathetic analysis of the challenges facing public interest groups seeking to educate the public in the face of well-financed opposition. A must for any social justice activist wishing to learn from the past, as well as why there is no such thing as a free lunch and how hard it can be to avoid biting the hand of those that feed us. I was particularly pleased to see the chronicling of how several long-time principled activists within the Canadian women’s health movement laid the foundation for important crossborder collaboration with US feminist activists that extends even to this day. Judy Norsigian, cofounder of the Our Bodies, Ourselves organization and co-author and co-editor of Our Bodies, Ourselves
As a public intellectual whose work spans the worlds of journalism, the women’s movement, breast cancer advocacy, and the social studies of medicine, Sharon Batt provides a nuanced analysis of the vexing problem of political advocacy and industry funding. This book has important implications not only for health policy and patient advocacy but also for the broader political conversation about neoliberalism, democracy, social movements, and social fairness. David J. Hess, professor of sociology, Vanderbilt University, and author of Undone Science: Social Movements, Mobilized Publics, and Industrial Transitions
This riveting history of the breast cancer movement chronicles, analyzes, and evaluates the relationship between patient advocacy organizations and the pharmaceutical industry. The author’s auto-ethnographic observations shine brilliantly, and the issues she raises should incite debate about the need for medical reform and new health policy. Sergio Sismondo, Professor of Philosophy, Queen’s University, and co-editor of The Pharmaceutical Studies Reader
Sharon Batt was a pioneer of the breast-cancer patients’ movement. No one is better positioned to tell the ultimate insider story of how the movement grew, feuded, and was slowly sundered by Big Pharma’s clever seductions. It’s a blistering but balanced study of the impossible strains imposed on our medical system and those who struggle within it – a cautionary but constructive tale for our times. Michele Landsberg, journalist, breast cancer survivor, and author of Writing the Revolution
Sharon Batt, herself a breast cancer survivor, weaves the personal with the political to tell the story of how most of the breast cancer movement ended up in the arms of the pharmaceutical industry. Abandoned by the federal government as it increasingly adopted a set of neoliberal values, the patient breast cancer groups turned to the drug companies for funding, and in doing so lost their way. Joel Lexchin, MD, Professor Emeritus, Faculty of Health, York University and author of Doctors in Denial: Why Big Pharma and the Canadian Medical Profession Are Too Close for Comfort
Sharon Batt is an independent scholar and adjunct professor in the Department of Bioethics at Dalhousie University.


Introduction: The Secret War among Patient Groups

Part 1: Canada’s Health Care System Transformed – Neoliberalism and the Erosion of the Welfare State

1 Canada’s Health Policy Landscape

2 Health Advocacy Organizations in Canada

Part 2: From Grassroots to Contestation to Partnership – The Breast Cancer Movement and Big Pharma

3 Beginnings of the Breast Cancer Movement

4 Advocacy Redefined

5 The Movement Fractures over Pharma Funding

6 Pharma Funding as the New Norm

7 Advocacy Groups and the Continuing Struggle over the Pharma-Funding Question

Conclusion: The Fight for Medicine’s Soul

Appendix: Organizations and Their Members



Find what you’re looking for...
Stay Informed

Receive the latest UBC Press news, including events, catalogues, and announcements.

Read past newsletters
Current Catalogues
F2017 Scholarly Cover
F2017 Trade Cover
Publishers Represented
UBC Press is the Canadian agent for several international publishers. Visit our Publishers Represented page to learn more.